TMCnet News
EXPLOSIVE news on: (OTCBB:ISCO) - (OTCBB:DRSV) - (OTCBB:BMTI)(M2 PressWIRE Via Acquire Media NewsEdge) Rochester NY -- www.breakthroughstocks.net names (OTCBB:ISCO) International Stem Cell Corp., (OTCBB:DRSV) Debt Resolve, Inc., and (OTCBB:BMTL) BioMedical Technology Solutions Holdings, Inc. its "Resistance-Breakers of the day"! Visit: www.breakthroughstocks.net for current profiles. To feature your publicly traded company in our alerts email us at [email protected] ------------------------------------------------------------------------------------------------------------------------------------------------------------ Visit: www.breakthroughstocks.net About INTERNATIONAL STEM CELL CORPORATION (ISCO.OB) International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike all other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals across racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, develops a line of cosmeceutical products via its subsidiary Lifeline Skin Care and advances novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics do not. More information is available at ISCO's website, www.internationalstemcell.com. To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0 News Today: MOCEANSIDE, Calif., Aug 19, 2010 -- International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com, today announced that its stem cell therapeutic programs focused on protective, transparent corneas (CytoCor(TM)) in the front of the eye and the light-sensitive retinal tissue (CytoRet(TM)) in the back of the eye will be formalized into a new business unit, Cytovis(TM). Together these programs will leverage external and internal development, regulatory and commercial expertise in cellular ophthalmology to form a focused portfolio of complementary product candidates designed to address high unmet medical needs with apparent pharmacoeconomic and quality of life benefits. CytoCor is the brand name for ISCO's corneal tissue that can be derived from the company's proprietary parthenogenetic stem cells or commonly used embryonic stem cells. Research and development with partners Absorption Systems in the US, Sankara Nethralaya in India and Automation Partnership in the UK continues for the purpose of optimizing the tissue for transplantation in the 10 million people worldwide suffering from corneal vision impairment and as an alternative to the use of live animals and animal eyes in the $500+M market for safety testing of drugs, chemicals and consumer products. ISCO's goal in the coming months is to establish funding and infrastructure in India for accelerated development of CytoCor for the therapeutic application and to advance and implement the chemical testing application with partners in the US and Europe. CytoRet is the brand name for ISCO's stem cell-derived retinal tissue. ISCO is using its parthenogenetic stem cells to develop individual retinal pigmented epithelial ("RPE") cells and layered retinal structures internally and in collaboration with the laboratory of Dr. Hans Keirstead, Professor of Anatomy and Neurobiology at the University of California, Irvine. ISCO recently commenced a new research collaboration with UC Irvine to launch the next phase of its retinal studies with that institution, including preclinical trials. Potential therapeutic applications include retinitis pigmentosa, an untreatable inherited disease affecting about 100,000 Americans, and the dry form of age-related macular degeneration, a major cause of blindness in the elderly of the Western world. ISCO's goal is to establish functional proof of concept for RPE cellular therapy in models of human disease in the next twelve-eighteen months. Jointly referred to as Cytovis ("cyto" for cellular, "vis" for vision), these two cellular ophthalmology programs share a number of features and benefits. First, with the aging of the population worldwide and the growing number of work-related eye injuries in India, China and other major countries, the market opportunity is growing steadily. Second, there are strong pharmacoeconomic and quality-of-life rationales for full or partial vision restoration or delay of vision impairment diseases. Third, delivery of cells and tissues to the confined anatomy of the eye inherently provides for better safety and efficacy than, for example, the systemic circulation or the central nervous system. This will likely result in lower regulatory barriers and shorter and less costly development paths compared to that of anatomically deeper and more widespread diseases. Fourth, a number of eye diseases cannot be treated with surgery or traditional small molecule or protein therapeutics, yet cell and tissue therapy is proven to work but currently limited by availability of safe and sufficient cells and tissue from human donors. Finally, eye care development programs like CytoCor and CytoRet share a number of regulatory, development and commercial aspects that make it feasible for a relatively small team to produce substantial clinical outcomes and achieve competitive presence in the marketplace alone or in collaboration with dedicated partners. Brian Lundstrom, ISCO's President, says: "ISCO's proprietary parthenogenetic stem cell technology continues to form the foundation for the company's long term regenerative medicine therapy programs. In the nearer term, CytoCor and CytoRet's unique benefits in the field of cellular ophthalmology offer the potential for partnering and funding at a relatively early stage. Combined with the current and future revenue of Lifeline Cell Technology and the revenue potential of Lifeline Skin Care, scheduled for launch in the 4th quarter, Cytovis adds significantly to ISCO's diversity and value creation potential for its investor base in a cost-efficient fashion." ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- Visit: www.breakthroughstocks.net About Debt Resolve, Inc. Debt Resolve provides lenders, collection agencies, debt buyers and hospitals with a patent-protected online bidding system for the resolution and settlement of consumer debt as well as a collections and skip tracing solution that is effective at every stage of collection and recovery. The company is publicly held and trades on the OTC Bulletin Board under the symbol DRSV. Amended Quarterly Reports on Form 10-Q for the periods ended June 30, 2008 and September 30, 2008 will be filed to correct an erroneous accounting of common stock issuances, as further discussed in the Form 8-K dated August 14, 2009. Debt Resolve is headquartered in Tarrytown, New York. For more information, visit http://www.b2i.us/irpass.asp?BzID=1976&to=ea&s=0. News Today: ARRYTOWN, N.Y., Aug 19, 2010 -- Debt Resolve, Inc. (OTCBB:DRSV) (the "Company"), provider of the proprietary Debt Resolve(R) software to major banks and other businesses with large consumer debt portfolios, announced the completion of major financing and the continued restructuring of the balance sheet. The company also announced the addition of Jonathan C. Rich to the Company's Board of Directors. According to Debt Resolve President and CFO David Rainey, "This critical financing provides significant capital to re-energize and expand our sales and marketing effort and to finish major technology enhancements nearing completion. Also, starting in July 2009, we began to significantly restructure our balance sheet. With this new additional reduction to our balance sheet liabilities, we are near to completing our objective of reducing legacy liabilities to $2 million or less. Finally, we are very pleased to add someone with Jonathan Rich's experience to our Board of Directors. He will be a significant asset to the Company as we plan to grow rapidly." Completion of major financing On August 12, 2010, the Company consummated a private placement of an aggregate of 60 units, with each unit consisting of 250,000 shares of our common stock, par value $.001 per share, and a detachable, transferable warrant to purchase common stock, at a purchase price of $25,000 per unit or an aggregate purchase price of $1,500,000, to purchasers that qualified as accredited investors, as defined in Regulation D, pursuant to the terms of a Confidential Private Placement Memorandum dated June 10, 2010. Each warrant entitles the holder to purchase 250,000 shares of common stock at an exercise price of $0.25 per share through August 12, 2015. Debt Resolve expects to use the net proceeds of the private placement to fund sales initiatives, strategic alliances and technology enhancements, and for working capital. James Brakke, Debt Resolve's CEO and Co-Chairman, stated, "Since becoming CEO, we have worked with several parties to complete this significant financing. The closing represents a milestone in our efforts to complete the restructuring of the Company." Restructuring of balance sheet Under the terms of the financing, the Company can use 20% of the proceeds to continue its balance sheet restructuring process. For cash payments of $319,935 (plus minimal accrued interest in some cases), the Company will remove $3,367,609 in additional liabilities from its balance sheet. This amount is in addition to the $6,106,285 reduction previously disclosed in our press release dated March 9, 2010. Also, Jonathan C. Rich, the Executive Vice President and Head of Investment Banking of National Securities Corporation, was elected to our Board of Directors effective on August 12, 2010. Mr. Rich, age 41, has been the Executive Vice President and Head of Investment Banking of National Securities Corporation, a full-service investment banking firm, since July 2008. Mr. Rich had been the Executive Vice President and Director of Investment Banking of vFinance Investments, Inc. since July 2005, and assumed his current position with National Securities when vFinance was acquired by National Securities in July 2008. Mr. Rich had previously served as Senior Vice President and Managing Director of Corporate Finance at First Colonial Financial Group since January 2001. First Colonial Financial was, in turn, acquired by vFinance in July 2005. Mr. Rich graduated from Tulane University with an interdisciplinary major in economics, political science, history and philosophy and received a joint J.D. / M.B.A. degree from Fordham University with a concentration in corporate finance. James Burchetta, Debt Resolve's Co-Chairman, stated, "The Company's focus will now change from restructuring to business development. We will be augmenting our team in this area in the near future, and I welcome Jonathan Rich to the Board and look forward to benefiting from his counsel." ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- Visit: www.breakthroughstocks.net About BioMedical Technology Solutions Holdings, Inc. BioMedical Technology Solutions Holdings, Inc., located in Englewood, Colorado, sells the Demolizer(R) II through its wholly owned subsidiary BioMedical Technology Solutions, Inc. BMTS' patented Demolizer(R) Technology converts infectious biomedical waste into non-infectious material. BMTS' products provide biomedical waste treatment solutions for the over 1,000,000 low to medium volume medical waste generators in the US and a global market five times larger than the US. For more information, visit http://www.bmtscorp.com/ or call 866-525-2687. About the Demolizer(R) II The Demolizer(R) II is the GREEN alternative to biomedical waste disposal. The device is the only patented, portable, and self-contained system able to process both sharps and typical red bag biomedical waste onsite. The processed waste is rendered sterile and discarded as common trash eliminating up to 100% of the cost associated with its disposal. The Demolizer(R) II meets or exceeds all EPA and CDC guidelines and is approved or meets treatment requirements in 48 states after review by 80 governmental agencies. The device uses no chemicals or liquids, plugs into a normal outlet through a surge protector, and automatically records and prints state required documentation. The Demolizer(R) II provides a safer, more environmentally GREEN method for biomedical waste disposal. News Today: ENGLEWOOD, CO, Aug 19, 2010 BioMedical Technology Solutions Holdings, Inc. ("BMTS") (OTCBB: BMTL) is pleased to announce the collaboration with International Medical Waste Services, Inc. ("IMWS") for international distribution and domestic rental distribution of BMTS' Demolizer(R) II System. IMWS is led by former BMTS Director and General Counsel, Gex F. Richardson. Mr. Richardson recently resigned as Director and General Counsel to devote his energies full time to spearheading the international sales and the domestic rental markets. After proper due diligence, it has been determined that the initial focus will target the South American market. Mr. Richardson and his associates have been working closely with the Department of Commerce who is assisting in these international expansion efforts. IMWS is also establishing a one-of-a-kind rental program allowing medical waste generators to rent the Demolizer(R) II System for the safe, simple, and secure onsite treatment of their medical waste at a fraction of the cost they are currently paying for third-party hauling services. Don Cox, President and CEO of BMTS, stated, "While we will miss Gex as a Board Member, we are very excited to have him and his team as distributors. Their extensive backgrounds and contacts in the waste industry, coupled with their years of international business and trade experience will be a valuable asset for our growth and the international promotion of the Demolizer(R) II System." Mr. Cox continued, "While we are presently making solid headway in our U.S. sales and conducting ongoing meetings with government agencies and major health corporations, we have only begun to tap the potential of rentals. The domestic rental market is extremely large and we believe that the team at IMWS will be a tremendous asset as we continue to expand our footprint in the industry." ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- Visit: www.breakthroughstocks.net About BREAKTHROUGHSTOCKS.NET BREAKTHROUGHSTOCKS.NET is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by BREAKTHROUGHSTOCKS.NET. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed. ((Comments on this story may be sent to [email protected])) (c) 2010 M2 COMMUNICATIONS |